Andy Gersteling

With experience in all phases of clinical trials, including first-in-human vaccine studies, Andy has managed trials in Australia, New Zealand, South Korea, Hong Kong, Singapore, Taiwan, the U.S., and Europe. As project leader, he focuses on meeting client objectives and key study deliverables.

His tenure with Parexel, which began in 2010, encompasses management of studies spanning indications including oncology, respiratory, infectious disease, rheumatology, neurology, ophthalmology, hematology, and vaccines.